Podofilox - @ - Topical destructive agents
Drug Name:
Podofilox - @ - Topical destructive agents
List Of Brands:
Indication Type Description:
Drug Interaction:
Not available
Adverse Reaction:
Adverse Reactions-
Treated with Podofilox 0.5% gel
Mild Moderate Severe
Bleeding 18% 3% 0.5%
Burning 35% 24% 10%
Erosion 25% 20% 8%
Inflammation 30% 30% 8%
Itching 30% 15% 6%
Pain 20% 20% 10%
Contra-Indications:
Hypersensitivity
Special Precautions-
Cutaneous use only - avoid contact with eyes. If contact, with the eye occurs, patients should immediately flush the eyes with copious amount of water and contact doctor
Flammable - drug product if flammable. Keep away from open flame
Pregnancy- Should be used in pregnancy only if the potential benefit justifies the potential risk to fetus.
Lactation- Decide to discontinue nursing or the drug depending on the importance of drug
to the mother
Children- safety and fficacy in pediatric patients have not been established
Dosages/ Overdosage Etc:
Indication-
Warts
Dosage-
Apply twice daily every 12 hours eg. morning and evening for 3 consecutive days theh with hold for 4 consecutive days
This 1 week cycle treatment may be repeated until there is no visible wart tissue for a maximum of 4 cycles.
If there is incomplete response after 4 consecutive treatment cycles, discontinue treatment
and consider alternative treatment.
Patient Information:
1. Only use this medication as directed by the physician
2.Instruct patients ro wash hands throughly before and after each application
3. Advice patients not to use this medication for any other than for which it was prescribed
4. Patients should report any adverse reaction to their doctor.
5. If improvement is not seen after 4 cycles of treatment, discontinue the medication
and consult your doctor
Pregnancy and lactation:
Pregnancy-
Should be used in pregnancy only if the potential benefit justifies the potential risk
to fetus.
Lactation-
Decide to discontinue nursing or the drug depending on the importance of drug
to the mother
Children-
Safety and fficacy in pediatric patients have not been established